These findings highlight the effectiveness of inhibiting TYMS and PLK1 in impeding melanoma progression and reducing chemoresistance, suggesting that combination therapy has the potential to improve survival and overall outcomes for melanoma patients. The gene discussed is TYMS; the disease is melanoma.